Skip to search formSkip to main contentSkip to account menu

Ensituximab

Known as: Anti-CPAA Monoclonal Antibody NPC-1C, Anti-Colorectal and Pancreatic Carcinoma-Associated Antigen Monoclonal Antibody NPC-1C, NPC-1C 
A chimeric monoclonal antibody against human colorectal and pancreatic carcinoma-associated antigens (CPAAs) with potential immunomodulating and anti… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer
Purpose: Patients with metastatic colorectal cancer refractory to chemotherapy have limited treatment options. Ensituximab (NEO… 
2017
2017
Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial.
3081Background: E is an investigational, novel, chimeric monoclonal IgG1 antibody derived from an immunogenic neoantigen with… 
2016
2016
A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial…
500 Background: NEO-102 is a novel chimeric mAb targeting a variant of MUC5AC with specificity to colorectal cancer. Its… 
2015
2015
A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC).
240 Background: NPC-1C (NEO102) is a novel chimeric monoclonal antibody that recognizes a variant form of MUC5AC expressed… 
2013
2013
A phase II study of NPC-1C: A novel therapeutic monoclonal antibody (mab) to treat pancreatic (P) and colorectal (CR) cancers.
3070 Background: NPC-1C is a chimeric mab developed to treat P and CR cancers. This mab was selected from a panel of hybridomas… 
2012
2012
A phase I safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.
233 Background: NPC-1C (NEO-101; ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment… 
Review
2012
Review
2012
Novel agents in early phase clinical studies on refractory pancreatic cancer.
The standard current treatment options in advanced pancreatic cancer have demonstrated minimal or modest only efficacy for the… 
2012
2012
A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.
233 Background: NPC-1C (NEO-101; ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment… 
2011
2011
Development of a new stool biomarker ELISA for the early detection of colorectal cancer.
e14128 Background: An ELISA was developed using NPC-1C, a novel antibody that reacts with an antigen expressed specifically by… 
2011
2011
Development of a new stool biomarker ELISA for the early detection of colorectal cancer.
390 Background: An ELISA was developed using NPC-1C, a novel antibody that reacts with an antigen expressed specifically by human… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)